Stealth™ Therapeutic Systems: Rationale and Strategies

  • Daan J. A. Crommelin
  • Gert Storm
Part of the NATO ASI Series book series (NSSA, volume 300)


In this chapter the reasons to develop’ stealth’ therapeutic systems for intravenous administration are discussed and strategies to achieve this goal are outlined. In particular, attention is paid to alternatives for polyethylene glycol as’ stealth’ inducing agent.


Sialic Acid Poly Lactic Acid Circulation Time Polymeric Micelle Carrier System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bazile, D., Prud’homme, C, Bassoullet, M-T., Marlard, M., Spenlehauer, G., and Veillard, M., 1995, Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocyte system, J. Pharm. Sci. 84:493.PubMedCrossRefGoogle Scholar
  2. Blume, G., Cevc, G., Crommelin, D.J.A., Bakker-Woudenberg, I.A.J.M., Kluft, C., and Storm, G., 1993, Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times, Biochim. Biophys. Acta. 1149:180.PubMedCrossRefGoogle Scholar
  3. Braeckman, R., 1997, Pharmacokinetics and pharmacodynamics of peptide and protein drugs, in: Pharmaceutical Biotechnology, D.J.A. Crommelin and R. Sindelar, eds., Harwood Science Publ., Amsterdam.Google Scholar
  4. Emanuel, E., Kedar, E., Bolotin, E.M., Smorodinsky, N.I., and Barenholz, Y., 1996a, Preparation and characterization of doxorubicin-loaded sterically stabilized immuno-liposomes, Pharm. Research, 13:352.CrossRefGoogle Scholar
  5. Emanuel, E., Kedar, E., Bolotin, E.M., Smorodinsky, N.I., and Barenholz, Y., 1996b, Targeted delivery of doxorubicin via sterically stabilized liposomes: pharmacokinetics and biodistribution in tumor-bearing mice, Pharm. Research, 13:861.CrossRefGoogle Scholar
  6. Fernandes, A.I., and Gregoriadis, G., 1996, Synthesis, characterization and properties of sialylated catalase, Biochim. Biophys. Acta, 1293:90.PubMedCrossRefGoogle Scholar
  7. Fernandes, A.I., and Gregoriadis, G., 1997, Polysialylated asparaginase: preparation, activity and pharmacokinetics, Biochim.Biophys. Acta, 1341:26.PubMedCrossRefGoogle Scholar
  8. Gregoriadis, G., 1978, Liposomes in therapeutic and preventive medicine: the development of the drug-carrier concept. In: Liposomes and their uses in Biology and Medicine, D. Papahadjopoulos, ed., New York Academy of Sciences, New York.Google Scholar
  9. Huang, L., ed., 1992, Forum: Covalently attached polymers and glycans to alter the biodistributiom of liposomes, J. Liposome Research, 2:289.Google Scholar
  10. Jain, R.K., 1996, Whitaker Lecture: delivery of molecules, particles and cells to solid tumors, Ann Biomed. Eng 24:457.PubMedCrossRefGoogle Scholar
  11. MacEwen, E.G., Rosenthal, R., Matus, R., Viau, A.T., and Abuchowski, A., 1987, A preliminary study on the evaluation of asparaginase — polyethyleneglycol conjugate against canine malignant lymphoma. Cancer Res. 59:2011.Google Scholar
  12. Maruyama, K., Takizawa, T., Yuda, T., Kennel, S.J., Huang, L., and Iwatsuru, M, 1995, Targetability of novel immunoliposomes modified with amphipatic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim.Biophys. Acta 1234:74.PubMedCrossRefGoogle Scholar
  13. Okano, T., Yui, N., Yokoyama, M., and Yoshida, R., 1994, Advances in Polymeric Systems for Drug Delivery, Gordon and Breach Science Publ., Switzerland.Google Scholar
  14. Poste, G., 1985, Drug targeting in cancer therapy, in: Receptor-Mediated Targeting of Drugs, G. Gregoriadis, G. Poste, J. Senior, and A. Trouet, NATO ASI Series, Series A: Life Sciences, Plenum Press, New York.Google Scholar
  15. Schauer, R., 1985, Sialic acid and their role as biological masks, TIBS September 1985:357.Google Scholar
  16. Seymour, L.W., 1992, Passive tumour-targeting of macromolecules and drug conjugates, Crit. Rev. Ther. Drug Carrier Systems, 9:135.Google Scholar
  17. Storm, G., Belliot, S.H., Daemen, T., and Lasic, D.D., 1995, Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system, Adv. Drug Delivery Rev. 17:31.CrossRefGoogle Scholar
  18. Storm, G., Bakker-Woudenberg, I.A.M.J., Schiffelers, R., Oyen, W.J.G., Crommelin, D.J.A., Corstens, F.H.M., and Boerman, O.C., Diagnostic and therapeutic targeting of infectious and inflammatory diseases using sterically stabilized liposomes, this book.Google Scholar
  19. Takakura, Y., and Hashida, M., 1996, Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm.Res. 13:820.PubMedCrossRefGoogle Scholar
  20. Torchilin, V.P., Klibanov, A.L., Huang, L., O’Donnell, S., Nossif, N.D., and Khaw, B.A., 1992, Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium, FASEB J., 6:2716.PubMedGoogle Scholar
  21. Torchilin, V.P., and Trubetskoy, V.S., 1995, Which polymers can make nanoparticulate drug carriers long-circulating?, Adv. Drug Delivery Reviews, 16:141.CrossRefGoogle Scholar
  22. Woodle, C., and Lasic, D.D., 1992, Sterically stabilized liposomes, Biochim.Biophys. Acta 1113:171.PubMedCrossRefGoogle Scholar
  23. Woodle, M.C., Storm, G., Newman, M.S., Jekot, J., Collins, L.R., Martin, F.J., and Szoka, F.C., 1992, Prolonged systemic delivery of peptide drugs by long circulating liposomes: illustration with vasopressin in BRATTLE BORO rat. Pharm. Res., 9:260.PubMedCrossRefGoogle Scholar
  24. Woodle, M., and Storm, G., eds., 1997, Long Circulating Liposomes. Old Drugs New Therapeutics, Springer Verlag, NY.Google Scholar
  25. Yamanauchi, H., Yano, T., Kato, T., Tanaka, I., Nakabayashi, S., Higashi, K., Miyoshi, S., and Yamada, H., 1995, Effects of sialic acid derivative on long circulation time and tumor concentration of liposomes. J. Controlled Rel. 113:141.Google Scholar
  26. Yokoyama, M., Okano, T., Sakurai, Y., Ekimoto, H., Shibazaki, C, and Kataoka, 1991, Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood, Cancer Res. 51:3229.PubMedGoogle Scholar
  27. Zalipsky, S., Hansen, C.B., Oaks, J.M., and Allen, T.A., 1996, Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes. J. Pharm. Sci. 85:133.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Daan J. A. Crommelin
    • 1
  • Gert Storm
    • 1
  1. 1.Utrecht Institute for Pharmaceutical SciencesUtrecht UniversityUtrechtThe Netherlands

Personalised recommendations